United States· US:76385-102_8199ccba-1a57-43f1-bbdc-70b6720b72c3
Primaquine Phosphate
A primaquine product containing primaquine phosphate, registered in United States by Unichem Pharmaceuticals (USA), Inc.. The same ATC class is registered in 7 of our 19 countries.
Checked against FDA National Drug Code directory (United States) on
Informational only — not a medical device.
Where it is registered
Primaquine is registered in 7 of 19 countries.
Countries holding a registration under ATC P01BA03 (primaquine), each read from that country’s own register.
- This record: United States, from FDA National Drug Code directory (United States)
- 4 of them publish a price we can compare per daily dose
Primaquine · ATC P01BA03
7 / 19 countries
- Canada
- Czechiaprice
- Franceprice
- Japan
- Norwayprice
- United Kingdom
- United Statesprice
The record
At a glance
FDA National Drug Code directory (United States)- Active substance
- PRIMAQUINE PHOSPHATE
- Manufacturer
- Unichem Pharmaceuticals (USA), Inc.
- Country
- United States (US)
- ATC code
- P01BA03
- ATC class
- Primaquine
- Defined daily dose
- 15 mg, O
- Reimbursed
- Not published by this register
- Source register
- FDA National Drug Code directory (United States)
- Last checked
- September 27, 2026
Packs & prices · 2
- ndc117638510201100 TABLET in 1 BOTTLE (76385-102-01)
- ndc1176385-102-01
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
348 interactions on record for primaquine.
Graded by severity as the source publishes them — 88 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Primaquine · interactions on record
348 records
- 88 severe
- 255 moderate
- 5 minor
Most severe, free to view
- PapaverineA03AD01severe
- CisaprideA03FA02severe
- DolasetronA04AA04severe
- QuinidineC01BA01severe
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Primaquine in 6 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- CzechiaPRIMAQUINE
- FrancePRIMAQUINE SANOFI 15 mg, comprimé pelliculéSANOFI WINTHROP INDUSTRIE
- United KingdomPrimaquine 15mg tabletsImported (United States)
- CanadaPRIMAQUINESANOFI-AVENTIS CANADA INC
- Japanプリマキンリン酸塩サノフィ
- NorwayPrimaquine phosphate sanofiSanofi-Synthelabo
Authorised across Europe · EMA
The same active substance is authorised in 2 EEA countries. Names it is sold under:
- Cyprus · Primaquine Remedica
- France · Primaquine Sanofi
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of FDA National Drug Code directory (United States). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/b2b482bf-852d-4798-8a27-d4f55217418d GET /v1/drugs/b2b482bf-852d-4798-8a27-d4f55217418d?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"route": "ORAL",
"source": "ndc",
"strength": "15",
"substance": "PRIMAQUINE PHOSPHATE",
"productndc": "76385-102",
"dosage_form": "TABLET",
"dea_schedule": null,
"strength_unit": "mg/1",
"application_number": "ANDA204476",
"marketing_category": "ANDA"
}See everything about primaquine.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.